Trial
NCT01784861
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Washington University School of Medicine
Collaborators
Tyrogenex
Condition
Adenocarcinoma
Intervention
X-82
Why stopped
Pharmaceutical company decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-07-08